Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Novartis builds radioligand therapy franchise; BMS pioneers new checkpoint inhibitors; Russian CRO leader tries to keep Ukraine trials going; Indian pharma and celebrity endorsement; and how R&D spend compares to 10 years ago.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 25 March 2022, including: Novartis AG builds radioligand therapy franchise; Bristol Myers Squibb Company pioneers new checkpoint inhibitors; Russian CRO leader tries to keep Ukraine trials going; Indian pharma and celebrity endorsement; and how R&D spend compares to 10 years ago.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Novartis Lays A New Foundation In Prostate Cancer With Second Radioligand Launch" - Scrip, 23 Mar, 2022.)
(Also see "BMS Wins Competition For Novel Checkpoint Inhibitors With Relatlimab Approval" - Scrip, 21 Mar, 2022.)
(Also see "The Russian-Born CRO Leader Trying To Keep Clinical Trials Going In Ukraine" - Scrip, 24 Mar, 2022.)
(Also see "Star Power: How Celebrity Endorsement Is Shaping In India Pharma" - Scrip, 21 Mar, 2022.)
(Also see "Up, Up And Away: A Comparison Of Industry R&D Spend Now Versus 10 Years Ago" - Scrip, 17 Mar, 2022.)